Myriam Nabhan

Myriam Nabhan
University College Dublin | UCD · Systems Biology Ireland

PhD

About

14
Publications
625
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
57
Citations
Citations since 2016
14 Research Items
57 Citations
201620172018201920202021202205101520
201620172018201920202021202205101520
201620172018201920202021202205101520
201620172018201920202021202205101520
Additional affiliations
May 2021 - present
University College Dublin
Position
  • PostDoc Position
September 2019 - April 2021
Université Paris-Saclay
Position
  • Lecturer
Education
October 2016 - December 2019
Université Paris-Saclay
Field of study
  • Immunology
September 2015 - June 2016
Université Paris-Saclay
Field of study
  • Immunology
September 2010 - June 2015

Publications

Publications (14)
Article
Full-text available
Sucrose is a commonly used stabilizing excipient in protein formulations. However, recent studies have indicated the presence of nanoparticulate impurities (NPIs) in the size range of 100–200 nm in pharmaceutical-grade sucrose. Furthermore, isolated NPIs have been shown to induce protein aggregation when added to monoclonal antibody formulations. M...
Article
The development of anti-drug Abs in response to biological products (BP) is a major drawback in the treatment of patients. Factors related to the patient, the treatment, and the product can influence BP immunogenicity. Among these factors, BP aggregates have been suggested to promote immunogenicity by acting as danger signals recognized by dendriti...
Article
Full-text available
Patients treated with bioproducts (BPs) frequently develop anti-drug antibodies (ADAs) with potential neutralizing capacities leading to loss of clinical response or potential hypersensitivity reactions. Many factors can influence BP immunogenicity and could be related to the patient, the treatment, as well as to the product itself. Among these lat...
Thesis
Full-text available
L’immunogénicité des biothérapies constitue une limitation majeure au traitement des patients atteints de maladies chroniques et se traduit par la production d’anticorps dirigés contre le biomédicament (anti-drug antibodies, ADA). La détection d’ADA de haute affinité et d’isotypes divers chez les patients suggère la mise en place d’une réponse immu...
Article
The presence of protein aggregates in biological products is suggested to promote immunogenicity, leading to the production of anti-drug antibodies with neutralizing capacities. This suggests a CD4+ T-cell dependent adaptive immune response, thus a pivotal role for antigen-presenting cells, such as dendritic cells (DCs). We previously showed that h...
Article
Full-text available
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of anti-drug antibodies (ADA) that consequently may result in reduced serum drug concentrations, a loss of efficacy or potential hypersensitivity reactions. Among other factors, aggregated antibodies have been suggested to promote immunogenicity, thus enha...
Article
Allergic contact dermatitis (ACD) is a major cause of occupational skin disease and nickel is among the most prevalent contact allergen. Dendritic cells (DCs) play an important role in ACD and in the type of the ensuing immune response through differential phenotypes and cytokines production. The interleukin (IL)-12 cytokine family is composed of h...

Network

Cited By

Projects

Project (1)
Project
Patients treated with biological products (BP) frequently develop anti-drug antibodies (ADA) with potential neutralizing capacities leading to loss of clinical response. Among other factors, BP aggregates have been suggested to promote immunogenicity, as they seem to be correlated with ADA development. Moreover, the presence of ADA suggests a CD4 T-cell dependent adaptive immune response and therefore a pivotal role for antigen presenting cells, such as dendritic cells (DC). The aim of our project was to determine how BP aggregates participate in DC activation and T-cell response leading to BP immunogenicity.